These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38457215)

  • 1. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
    Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
    Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.
    Yu S; Lin T; Nie D; Zhang Y; Sun Z; Zhang Q; Wang C; Xiong M; Fan Z; Huang F; Xu N; Liu H; Yu G; Zhang H; Shi P; Xu J; Xuan L; Guo Z; Wu M; Han L; Xiong Y; Sun J; Wang Y; Liu Q
    Blood Cancer J; 2021 Dec; 11(12):195. PubMed ID: 34873148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
    Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
    JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood
    van Weelderen RE; Klein K; Harrison CJ; Jiang Y; Abrahamsson J; Arad-Cohen N; Bart-Delabesse E; Buldini B; De Moerloose B; Dworzak MN; Elitzur S; Fernández Navarro JM; Gerbing RB; Goemans BF; de Groot-Kruseman HA; Guest E; Ha SY; Hasle H; Kelaidi C; Lapillonne H; Leverger G; Locatelli F; Masetti R; Miyamura T; Norén-Nyström U; Polychronopoulou S; Rasche M; Rubnitz JE; Stary J; Tierens A; Tomizawa D; Zwaan CM; Kaspers GJL
    J Clin Oncol; 2023 Jun; 41(16):2963-2974. PubMed ID: 36996387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
    Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
    Zhou W; Chen G; Gong D; Gao Y; Yu L
    Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
    Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
    Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
    Othman J; Potter N; Ivey A; Jovanovic J; Runglall M; Freeman SD; Gilkes A; Thomas I; Johnson S; Canham J; Cavenagh J; Kottaridis P; Arnold C; Ommen HB; Overgaard UM; Dennis M; Burnett A; Wilhelm-Benartzi C; Dillon R; Russell NH
    Blood; 2024 May; 143(19):1931-1936. PubMed ID: 38364112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring
    Jiang B; Zhao Y; Luo Y; Yu J; Chen Y; Ye B; Fu H; Lai X; Liu L; Ye Y; Zheng W; Sun J; He J; Zhao Y; Wei G; Cai Z; Huang H; Shi J
    Cell Transplant; 2024; 33():9636897231225821. PubMed ID: 38270130
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
    Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
    Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
    Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.